PUBLISHER: Inkwood Research | PRODUCT CODE: 1094948
PUBLISHER: Inkwood Research | PRODUCT CODE: 1094948
The North America immunoglobulin market is predicted to record a CAGR of 6.95% during the forecasted period of 2022 to 2030. The market growth of the region is propelled by major factors such as the high incidence of various diseases, the presence of key industry players, and the growth in product approvals by the United States Food and Drug Administration (FDA).
The North America immunoglobulin market growth assessment covers the evaluation of Canada and the United States. In Canada, intravenous immunoglobulin is primarily distributed by the Canadian Blood System to the country's blood banks within hospital settings. Subsequently, hospital blood banks then dispense intravenous immunoglobulin to individual patients as prescribed. In addition, various institutions also maintain a comprehensive database inventory regarding the usage of the same. Intravenous immunoglobulin is licensed by Health Canada for the treatment of secondary and primary immune deficiencies, allogeneic bone marrow transplantation, idiopathic thrombocytopenic purpura, Kawasaki disease, chronic B-cell lymphocytic leukemia, as well as pediatric HIV-infection.
Over recent years, Canada has also recorded significant infrastructural development associated with immunoglobulin and plasma. This factor is set to have a positive impact on the country's market growth. Aligning with this, in 2019, Canadian Blood Services announced its proposition to open plasma donation sites across three provinces in order to secure the supply for patients. As a result, these factors are expected to supplement the growth of the immunoglobulin market in North America during the forecast period.
Top players operating in the market include: ADMA Biologics, Pfizer Inc, CSL Behring, etc.